Akebia Therapeutics, Inc. (AKBA)
Data as of , from SEC Form 4 filings.
No open-market insider trades (90d)Watch AKBA
See up to 3 months of AKBA. The 7-day demo opens the 1M and 3M ranges and puts AKBA on your watchlist.
Start 7-day demoLatest AKBA insider trades
Erik Ostrowski - OfficerOpen-market sale$62K
John P. Butler - OfficerOpen-market purchase$87K
About Akebia Therapeutics, Inc. (AKBA)
Akebia Therapeutics, Inc. files with the SEC under CIK 0001517022 and is classified as pharmaceutical preparations. It is grouped with Health Care companies on this site.
AKBA Form 4 activity by transaction type, last 90 days
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Option exercise | 2 | 700,000 |
Dollar totals cover purchases and sales only (codes P and S). Grants, option exercises, gifts and tax withholding are counted in shares, because none of them is a trade at a market price.
AKBA insider transactions (Form 4)
5226 Form 4 filings on record, the earliest from Jun 10, 2025, newest first.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| John P. Butler - Officer | Option exercise | Common Stock | 350,000 | $0.63 | $221K | |
| John P. Butler - Officer | Option exercise | Stock Option (Right to buy) | 350,000 | $0.00 | - | |
| Erik Ostrowski - Officer | Open-market sale | Common Stock | 56,019 footnote F1 | $1.11 | $62K | |
| ||||||
 Myles Wolf | Grant or award | Common Stock | 35,700 footnote F1 | $0.00 | - | |
| Myles Wolf | Grant or award | Stock Option (Right to buy) | 53,600 | $0.00 | - | |
| ||||||
| Cynthia Smith | Grant or award | Common Stock | 35,700 footnote F1 | $0.00 | - | |
| Cynthia Smith | Grant or award | Stock Option (Right to buy) | 53,600 | $0.00 | - | |
| ||||||
| Michael W. Rogers | Grant or award | Stock Option (Right to buy) | 53,600 | $0.00 | - | |
| Michael W. Rogers | Grant or award | Common Stock | 35,700 footnote F1 | $0.00 | - | |
| ||||||
| Ron Frieson | Grant or award | Stock Option (Right to buy) | 53,600 | $0.00 | - | |
| Ron Frieson | Grant or award | Common Stock | 35,700 footnote F1 | $0.00 | - | |
| ||||||
| Leanne M. Zumwalt | Grant or award | Stock Option (Right to buy) | 53,600 | $0.00 | - | |
| Leanne M. Zumwalt | Grant or award | Common Stock | 35,700 footnote F1 | $0.00 | - | |
| ||||||
| Adrian Adams | Grant or award | Stock Option (Right to buy) | 53,600 | $0.00 | - | |
| Adrian Adams | Grant or award | Common Stock | 35,700 footnote F1 | $0.00 | - | |
| ||||||
| Philip J. Vickers | Grant or award | Stock Option (Right to buy) | 214,400 | $0.00 | - | |
| John P. Butler - Officer | Open-market purchase | Common Stock | 69,270 footnote F1 | $1.25 footnote F2 | $87K | |
| ||||||
| Richard C. Malabre - Officer | Open-market sale | Common Stock | 36,142 footnote F1,F2 | $1.39 | $50K | |
| Richard C. Malabre - Officer | Open-market sale | Common Stock | 13,382 footnote F1,F3 | $1.39 | $19K | |
| ||||||
| Nicholas Grund - Officer | Open-market sale | Common Stock | 53,585 footnote F1,F2 | $1.39 | $74K | |
| Nicholas Grund - Officer | Open-market sale | Common Stock | 31,244 footnote F1,F3 | $1.39 | $43K | |
| ||||||
 Steven Keith Burke - Officer | Open-market sale | Common Stock | 21,582 footnote F1,F2 | $1.39 | $30K | |
| Steven Keith Burke - Officer | Open-market sale | Common Stock | 25,375 footnote F1,F3 | $1.39 | $35K | |
| Steven Keith Burke - Officer | Open-market sale | Common Stock | 20,701 footnote F1,F4 | $1.39 | $29K | |
| ||||||
 Carolyn M. Rucci - Officer | Open-market sale | Common Stock | 16,846 footnote F1,F2 | $1.39 | $23K | |
| Carolyn M. Rucci - Officer | Open-market sale | Common Stock | 25,382 footnote F1,F3 | $1.39 | $35K | |
| Carolyn M. Rucci - Officer | Open-market sale | Common Stock | 27,544 footnote F1,F4 | $1.39 | $38K | |
| ||||||
| Erik Ostrowski - Officer | Open-market sale | Common Stock | 34,951 footnote F1,F2 | $1.39 | $49K | |
| ||||||
| John P. Butler - Officer | Open-market sale | Common Stock | 46,660 footnote F1,F2 | $1.39 | $65K | |
| John P. Butler - Officer | Open-market sale | Common Stock | 96,065 footnote F2,F3 | $1.39 | $134K | |
| John P. Butler - Officer | Open-market sale | Common Stock | 114,891 footnote F2,F4 | $1.39 | $160K | |
| John P. Butler - Officer | Grant or award | Common Stock | 175,250 footnote F5 | $1.41 | $247K | |
| John P. Butler - Officer | Open-market sale | Common Stock | 83,689 footnote F2,F6 | $1.39 | $116K | |
| ||||||
| Nicholas Grund - Officer | Grant or award | Common Stock | 204,000 footnote F1 | $0.00 | - | |
| Nicholas Grund - Officer | Grant or award | Stock Option (Right to buy) | 320,000 | $0.00 | - | |
| ||||||
| Steven Keith Burke - Officer | Grant or award | Common Stock | 204,000 footnote F1 | $0.00 | - | |
| Steven Keith Burke - Officer | Grant or award | Stock Option (Right to buy) | 320,000 | $0.00 | - | |
| ||||||
| Carolyn M. Rucci - Officer | Grant or award | Common Stock | 190,000 footnote F1 | $0.00 | - | |
| Carolyn M. Rucci - Officer | Grant or award | Stock Option (Right to buy) | 270,000 | $0.00 | - | |
| ||||||
| Richard C. Malabre - Officer | Grant or award | Common Stock | 79,000 footnote F1 | $0.00 | - | |
| Richard C. Malabre - Officer | Grant or award | Stock Option (Right to buy) | 119,000 | $0.00 | - | |
| ||||||
| Erik Ostrowski - Officer | Grant or award | Common Stock | 204,000 footnote F1 | $0.00 | - | |
| Erik Ostrowski - Officer | Grant or award | Stock Option (Right to buy) | 320,000 | $0.00 | - | |
| ||||||
| John P. Butler - Officer | Grant or award | Common Stock | 743,000 footnote F1 | $0.00 | - | |
| John P. Butler - Officer | Grant or award | Stock Option (Right to buy) | 1,115,000 | $0.00 | - | |
| ||||||
| Erik Ostrowski - Officer | Open-market sale | Common Stock | 41,314 | $3.67 | $152K | |
| Adrian Adams | Grant or award | Common Stock | 35,700 | $0.00 | - | |
| Adrian Adams | Grant or award | Stock Option (Right to buy) | 53,600 | $0.00 | - | |
| Michael W. Rogers | Grant or award | Common Stock | 35,700 | $0.00 | - | |
| Michael W. Rogers | Grant or award | Stock Option (Right to buy) | 53,600 | $0.00 | - | |
| Leanne M. Zumwalt | Grant or award | Common Stock | 35,700 | $0.00 | - | |
| Leanne M. Zumwalt | Grant or award | Stock Option (Right to buy) | 53,600 | $0.00 | - | |
Item 5.02
Item 2.02, 9.01
Item 7.01, 8.01, 9.01
Item 5.07
Recent AKBA Form 144 notices of proposed sale
1An insider files Form 144 before selling restricted or control stock. It announces a planned sale. If the sale goes ahead, it shows up later on a Form 4.
| Filed | Filer | Relationship | Shares | Market value | Notice |
|---|---|---|---|---|---|
| - | - | - | - | View on EDGAR |
AKBA insider trading FAQ
What is the latest insider trade for AKBA?
Akebia Therapeutics, Inc. (AKBA) had 1 insider filing in the last 90 days, with the most recent on 2026-08-10. The full record for AKBA runs to 26 Form 4 filings, the earliest from 2025-06-10. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.
How many insiders are buying AKBA stock?
No insider purchases of AKBA were filed in the last 90 days. 1 purchase is on record for this company.
How many insiders are selling AKBA stock?
No insider sales of AKBA were filed in the last 90 days. 17 sales are on record for this company.
Where can I see AKBA SEC filings (Form 4, 10-K, 10-Q, 8-K)?
This page collects AKBA Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
More Health Care companies with insider activity
Recent insider filings
10The EDGAR links open each original Form 4, so you can check any number on this page against the filing it came from.
- - John P. Butler view on EDGAR
- - Erik Ostrowski view on EDGAR
- - Myles Wolf view on EDGAR
- - Cynthia Smith view on EDGAR
- - Michael W. Rogers view on EDGAR
- - Ron Frieson view on EDGAR
- - Leanne M. Zumwalt view on EDGAR
- - Adrian Adams view on EDGAR
- - Philip J. Vickers view on EDGAR
Related companies with recent insider activity
Learn more
- What the Form 4 transaction codes mean
- Grants, option exercises, gifts and tax withholding are not trades on the market. The codes say which is which.
- Form 144 vs Form 4
- A Form 144 announces a planned sale; the Form 4 reports it after it happens.
- Insider activity in Health Care
- Where AKBA's peers are being bought and sold.
- Every recent Form 4
- The market-wide feed, updated as filings arrive from SEC EDGAR.
Follow AKBA with a 7-day demo
- AKBA on your watchlist
- Every AKBA Form 4 filing on record
- Up to 3 months of AKBA price history
- The daily trading plan of ranked insider buys, on a delay, with the plan archive
Start 7-day demoCard required. Your card is never charged for the demo.
